Etanercept treatment in corticosteroid-dependent myasthenia gravis

Neurology

Volumn 63, Issue 12, 2004, Pages 2390-2392

  Rowin, J ^a   Meriggioli, M N ^a   Tuzun E ^c   Leurgans, S ^b   Christadoss, P ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; ETANERCEPT; PREDNISONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RASH; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 11144331435     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000147242.92691.71     Document Type: Article

References (10)

1. Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1998;42:233-284.
2. Goluszko E, Hjelmstrom P, Deng C, Poussin M, Ruddle NH, Christadoss P. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 2001;113:109-118.
3. Goluszko E, Deng C, Poussin MA, Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 2002;122:85-93.
4. Wang HB, Li H, Shi FD, Chambers BJ, Link H, Ljunggren HG. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 2000;12: 1381-1388.
5. Christadoss P, Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant tumor necrosis factor receptor Fc protein. J Neuroimmunol 2002;122:186-190.
6. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23.
7. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis. Validation and comparison with the QMG score. Ann NY Acad Sci 2003;998:440-444.
8. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52: 1487-1489.
9. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
10. Zou JX, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-564.